Thursday, February 9, 2012 Last update: 3:33 PM
The Best of U.S. Company Technology News
Submit Company story ideas to FreshNews.com. See our complete guidelines.
Trade Events
Alnylam Pharmaceuticals, Inc.
News articles for Alnylam Pharmaceuticals, Inc.:
Thursday, February 9, 2012
- Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial ResultsAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2011, and company highlights. ... read moreAlnylam Scientists Discover Novel Method for Monitoring RNAi Activity in Blood SamplesAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that its scientists have discovered a novel method for monitoring ... read more
Thursday, February 2, 2012
- Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2011 Financial ResultsAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the fourth quarter and year ending December 31, 2011 ... read more
Monday, January 30, 2012
- Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Second Generation Lipid Nanoparticles (LNP) for Systemic Delivery of RNAi ThAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has ... read more
Thursday, January 19, 2012
- Alnylam to Restructure Organization, Aligning Resources with Focus on Highest Value Pipeline Opportunities in “Alnylam 5x15™” Product StrategyAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it intends to implement a strategic corporate restructuring, including ... read more
Tuesday, January 17, 2012
- Alnylam Files Patent Infringement Suit Against TekmiraAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has filed a patent infringement lawsuit against Tekmira ... read more
Wednesday, January 4, 2012
- Alnylam to Webcast Presentation at 30th Annual J.P. Morgan Healthcare Conference 2012Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 30th Annual J.P. Morgan Healthcare ... read more
Tuesday, December 13, 2011
- Alnylam Scientists Present New Data on RNAi Therapeutics at 53rd ASH Annual MeetingAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it presented multiple posters and presentations at the 53rd ... read more
Tuesday, November 22, 2011
- Alnylam to Webcast Presentation at the Piper Jaffray 23rd Annual Health Care ConferenceAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Piper Jaffray 23rd Annual Health Care ... read more
Wednesday, November 16, 2011
- Alnylam Pharmaceuticals Grants InterfeRx™ Intellectual Property License to Sylentis for Development and Commercialization of RNAi TherapeuticsAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Sylentis, S.A., a Spanish bio-pharmaceutical company devoted to the research and development of new therapies based ... read more
Tuesday, November 15, 2011
- Alnylam to Present Phase I Clinical Data at VIIIth International Symposium on Familial Amyloidotic PolyneuropathyAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it will present new data from its ALN-TTR program ... read more
Tuesday, November 1, 2011
- Alnylam Pharmaceuticals Reports Third Quarter 2011 Financial ResultsAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2011, and company highlights. ... read moreAlnylam and GlaxoSmithKline Form Collaboration on RNAi Technology for Vaccine ProductionAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today it has formed a collaboration with GlaxoSmithKline (GSK) focused on ... read more
Tuesday, October 25, 2011
- Alnylam to Webcast Conference Call Discussing Third Quarter 2011 Financial ResultsAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the third quarter ending September 30, 2011 on Tuesday, ... read more
Thursday, October 20, 2011
- Alnylam to Webcast Presentation at the Newsmakers in the Biotech Industry 2011 ConferenceAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Newsmakers in the Biotech Industry 2011 ... read more
Tuesday, October 11, 2011
- Alnylam and Collaborators Publish New Pre-clinical Data on Delivery of RNAi Therapeutics to Key Cell Types Regulating Immune and Inflammatory DiseasesAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication of two peer-reviewed papers documenting systemic delivery of ... read more
Wednesday, September 21, 2011
- Alnylam to Webcast Presentation at the JMP Securities Healthcare ConferenceAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the JMP Securities Healthcare Conference on ... read more
Monday, September 12, 2011
- Alnylam to Webcast Presentation at the UBS Global Life Sciences ConferenceAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the UBS Global Life Sciences Conference on Monday, ... read moreAlnylam Scientists and Collaborators Report Significant New Advances in Delivery of RNAi Therapeutics at 2011 Oligonucleotides Therapeutics Society MeetingAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it presented multiple posters and presentations at the 7th ... read more
Thursday, September 8, 2011
- Alnylam Expands “Alnylam 5x15” RNAi Therapeutic Pipeline with ALN-APC, an RNAi Therapeutic Targeting Protein C for the Treatment of HemophiliaAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has selected its fourth program in its ‘Alnylam ... read more